联合检测胸液端粒酶和细胞角蛋白19片段对肺癌胸腔积液的诊断价值

The diagnostic evaluation of telomerase assay combined with CYFRA21-1 in pleural effusion of lung cancer

目的探讨联合检测肿瘤标记物端粒酶和细胞角质蛋白 19片段 (CYFRA2 1-1)对肺癌胸腔积液的诊断价值。方法采用聚合酶链反应 -酶联免疫吸附分析法 (PCR-ELISA)检测胸液端粒酶活性和免疫放射分析法测定胸液 CYFRA2 1-1水平 ,共检测了 3 6例肺癌胸腔积液和 3 3例非恶性胸腔积液。结果肺癌胸腔积液组的胸液端粒酶和 CYFRA2 1-1的阳性率分别为 77.8%和 72 .2 %。非恶性胸腔积液的端粒酶和 CYFRA2 1-1的假阳性率分别为 6.1%和 9.1%。结论检测胸液端粒酶和 CYFRA2 1-1对肺癌胸腔积液的诊断均有一定的价值 。

Objective To explore the diagnostic evaluation of telomerase assay combined with CYFRA21 1 in pleural effusion of lung cancer.Methods Telomerase activity and CYFRA21 1 from pleural effusion of 31 lung cancer cases and 33 non malignant pleural effusion cases were detected by PCR ELISA and IRA.Results The positive rates of telomerase and CYFRE21 1 in the pleural effusion of lung cancer patients were 77.8% and 72.2%,respectively.The false positive rates of telomerase and CYFRE21 1 in the non malignant pleural effusion were 6.1% and 9.1%,respectively.Conclusion The assay of telomerase and CYFRA21 1 of pleural fluid is valuable to the diagnosis of pleural effusion of lung cancer.The combination of the two assays can increase the accuracy of the diagnosis.